FDA Approves Vizz Eye Drops to Improve Near Vision in Adults
By Lori Solomon HealthDay Reporter
WEDNESDAY, Aug. 6, 2025 -- The U.S. Food and Drug Administration has approved Vizz 1.44 percent (aceclidine ophthalmic solution) for the treatment of presbyopia in adults.
Vizz is the first and only aceclidine-based eye drop to improve near vision in adults with presbyopia. Vizz contracts the iris sphincter muscle resulting in a pinhole effect, achieving a pupil <2 mm, which extends depth of focus to significantly improve near vision without causing a myopic shift.
The approval was based on data from phase 3 studies: CLARITY 1 and CLARITY 2 evaluated the safety and efficacy of Vizz in 466 participants dosed once daily for 42 days, while CLARITY 3 evaluated 217 participants for long-term safety over six months of once-daily dosing. Across trials, Vizz demonstrated improved near vision within 30 minutes that lasted up to 10 hours. There were no serious treatment-related adverse events observed across all three trials (30,000 treatment days). The most common reported adverse reactions (mostly mild, transient, and self-resolving) included installation site irritation, dim vision, and headache.
"This FDA approval represents a disruptive paradigm shift in treatment options for millions of people who are frustrated and struggling with the inevitable age-related loss of their near vision," Vizz clinical investigator Marc Bloomenstein, O.D., from the Schwartz Laser Eye Care Center in Scottsdale, Arizona, said in a statement. "I believe this will be a welcome solution for both optometrists and ophthalmologists who will now be able to offer a highly effective and sought-after presbyopia treatment that could immediately become the standard of care, with a product profile that will meet our patients' needs."
The approval of Vizz was granted to LENZ Therapeutics.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2025
Read this next
AI Can Help Screen For Vision-Destroying Diabetic Eye Disease
WEDNESDAY, July 16, 2025 — A new AI-powered retina tracker can help doctors screen for a vision-destroying diabetic eye disease, researchers say. The Simple Mobile AI...
Bausch + Lomb Issues Recall of enVista Lenses Used in Cataract Surgery
THURSDAY, April 10, 2025 -- Bausch + Lomb has announced a voluntary recall of intraocular lenses on its enVista platform due to the potential for an acute postoperative...
AI Outperforms Urgent Care Docs, Study Says
TUESDAY, April 8, 2025 -- Cough? Sore throat? UTI? Eye infection? Artificial intelligence (AI) might one day be seeing you for these sorts of conditions, a new study says. AI...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.